A Study Of MCG In Cardiac Amyloidosis
ConditionAmyloidosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorMayo Clinic
About this trial
The primary objective of this observational study is to evaluate the utility of magnetocardiography (MCG) in diagnosing and monitoring disease progression in patients with amyloidosis, and to assess its effectiveness in comparison to other modalities, such as ECG.
Eligibility criteria
Qualifiers
Age ≥ 18 years on the date of consent
Ability for participant to comply with study requirements
Written informed consent
Disqualifiers
Pregnant or breastfeeding
Having an active atrial fibrillation episode as seen on most current 12-lead ECG
Active thoracic metal implants (including pacemaker, insertable cardiac monitor, or internal defibrillator).
External electrical pads or devices (e.g. Pacer pads, ECG electrodes, heart rate patch), that must remain on patient's chest during MCG scan
Trial design
Treatments tested in this trial
- SandboxAQ CardiAQ Magnetocardiography
Treatment groups
500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov